+351 211 369 829 INFO@OPHIOMICS.COM

Ophiomics wins the SME Instrument Phase I

Ophiomics was granted the SME Instrument Phase I grant to conduct a Feasibility study for its HepatoPredict genomic signature for Liver Cancer. Check here for the CORDIS page. This grant will permit Ophiomics to build a business case for HepatoPredict.

Share the Post:

Related Posts

HepatoPredict: improved & better environmental footprint.

After a lot of under the hood work, we are happy to announce Version 2.0 of the HepatoPredict kit, more

New ambition, new image!

Ophiomics was founded in 2015 as clinical testing laboratory. In 2020, with the support of the EIC Accelerator grant and

Going global @ArabHealth

Ophiomics @ Arab Health 2023

🚀Off to #ArabHealth2023 with the #EUeic Overseas Trade Fairs ✈️Programme 2.0! Pay us a visit at the European Pavilion (Za’abeel Hall 6 – Booth Z6.C25).